Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects
Current Therapeutic Research, 07/31/09
Song M et al. – The plasma t½z did not appear to reflect the duration of suppression of gastric acid secretion: the t½z values of lansoprazole and the 2 metabolites were ~2 to 2.5 hours, while the acid–inhibitory effect lasted >24 hours. Cmax, AUC, and t½z of lansoprazole, and especially lansoprazole sulfone, varied. Differences in metabolism types and/or genotype of CYP2C19 should be taken into account when planning a lansoprazole dosing regimen.
Related Articles
Molecular mechanism and functional consequences of lansoprazole-mediated heme oxygenase-1 induction
World Journal of Gastroenterology, 10/06/09
Relevance Score: 87%
Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis
Clinical and Experimental Gastroenterology, 11/17/09
Relevance Score: 80%
Mylan Receives FDA Approval for Generic Version of Prevacid Through its Subsidiary Matrix Laboratories
Mylan, 11/11/09
Relevance Score: 80%
Acute Kidney Injury in Patients with Inactive Cytochrome P450 Polymorphisms
Renal Failure, 10/30/09
Relevance Score: 80%
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience
Alimentary Pharmacology and Therapeutics, 10/23/09
Relevance Score: 80%
Today in Pharmacokinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype
British Journal of Clinical Pharmacology, 11/30/09
Phase 1 Trial of Adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) Study Group
American Journal of Kidney Diseases, 11/30/09
Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide
British Journal of Clinical Pharmacology, 11/30/09
Sponsor
Article Search
Sponsor


See Latest Articles


